BCA
ALPN

Berman Capital Advisors’s Alpine Immune Sciences Inc ALPN Stock Holding History

Berman Capital Advisors’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-54,524
Closed -$529K – 1815
2020
Q2 		$529K Buy
+54,524
New +$236K 0.14% 67

Other funds holding ALPN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Berman Capital Advisors's ALPN Position: Q3 2020 in Review

Berman Capital Advisors sold out of Alpine Immune Sciences Inc (ALPN) in Q3 2020, closing a stake of 54,524 shares — an estimated $529K sold.

Berman Capital Advisors first reported a position in ALPN in Q2 2020 and held it in 1 quarter. The position peaked at $529K in Q2 2020. 35 funds tracked by Wall St. Rank hold ALPN as of Q3 2020.

  • Berman Capital Advisors reported no remaining Alpine Immune Sciences Inc position as of Q3 2020 after selling out during the quarter.
  • Berman Capital Advisors sold 54,524 Alpine Immune Sciences Inc shares in Q3 2020, an estimated $529K.
  • Berman Capital Advisors first reported a position in Alpine Immune Sciences Inc in Q2 2020 and held it in 1 quarter.
  • Berman Capital Advisors's Alpine Immune Sciences Inc position peaked at $529K in Q2 2020.
  • 35 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q3 2020.

Based on Berman Capital Advisors's 13F filing for Q3 2020, filed 5 Nov 2020.